Contact Us

Southern California Community Clinic Recognized Nationally for its Leading Pharmacy Program

Center for Inherited Blood Disorders is the first hemophilia treatment center in the nation to be named a leading practice site by the Health Resources & Services Administration's Office of Pharmacy Affairs
    ORANGE, CA, February 06, 2014 /24-7PressRelease/ -- The Center for Inherited Blood Disorders (CIBD), a federally-recognized Hemophilia Treatment Center (HTC) in Orange, was named by the Health Resources & Services Administration's (HRSA) Office of Pharmacy Affairs as a 2013-2015 Leading Practice Site in its 340B Peer-to-Peer Program . CIBD is the first HTC in the country to be named a Leading Practice Site, and the only Leading Practice Site in California.

Leading sites are selected by the HRSA for their attention to compliance, and exemplary performance in the 340B program, a federal pharmacy discount program. After an application process and site visit, HRSA selects Leading Sites based on five areas of practice: access to affordable medications, efficient business practices, outcomes-driven pharmaceutical care, quality assurance, and program integrity. CIBD is one of 26 federally-recognized Leading Practice Sites in the United States out of 3,800 340B pharmacy programs.

"Providing access to affordable health care, diligently, has always been a hallmark of CIBD," remarked Isabel Becerra, CEO of the Coalition of Orange County Community Health Centers. "It's a pleasure to see their pharmacy receive this honor."

The 340B Peer-to-Peer Program was created in 2011 by the HRSA Office of Pharmacy Affairs (OPA) to spotlight high performing 340B pharmacies and to recognize them as Leading Practice Sites. Recognized sites serve as mentors to other 340B entities. Recipients receive a $20,000 stipend which can be used to develop student and residency education programs, helping to expand the local healthcare workforce.

According to Kimberly Cripe, CEO of CHOC Children's Hospital of Orange County-one of CIBD's healthcare partners-the recognition is well deserved. "Some of our patients have benefited from this hemophilia treatment center for most of their lives. This distinction is well earned."

CIBD founder and medical director Diane Nugent, M.D. credits the Center's pharmacy team. "Their commitment to integrity and quality service will indeed serve as a role model to other 340B pharmacy programs in the state and region."

The Center for Inherited Blood Disorders (CIBD), a 501(c)(3) non-profit, is one of 130 HTC facilities nationwide recognized by the CDC and HRSA. CIBD is the federally-recognized HTC for Orange, Riverside, San Bernardino, and parts of Los Angeles counties. For over 10 years, CIBD's specialists in adult and pediatric rare inherited blood disorders have been providing education, support, and services while coordinating care with family doctors, all while helping people with bleeding disorders live longer, healthier lives. CIBD is the regional grantee for the Western States/Region IX providing leadership and oversight to 14 HTC facilities in California, Hawaii, Nevada, and Guam. CIBD serves more than 500 patients each year and is a designated Covered California site with certified enrollment counselors.

The 340B Pharmacy Program enables eligible safety net health care organizations such as hospitals, cancer treatment centers, community health centers, and specialized clinics to purchase medicines at a discounted rate, passing the savings onto their state, county, and third-party payers, and re-investing revenues in order to care for more patients, and expand services.

# # #

Read more Press Releases from Lizz Mishreki:

Contact Information

Lizz Mishreki
Mishreki PR

Mission Viejo, CA
Voice: (949) 280-5515
E-Mail: Email Us Here
Website: Visit Our Website

Like This Story?

I like it! 0


If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release Newswire. We are unable to assist you with any information regarding this release. 24-7 Press Release Newswire disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.